OPEN END TURBO PUT WARRANT - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 15:43:04 17/06/2024 BST | ||
| 23.29 EUR | -1.44% |
|
| Current month | -19.02% | ||
| 1 month | -31.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 23.29 | -1.44% |
| 14/06/24 | 23.63 | -1.71% |
| 13/06/24 | 24.04 | -1.64% |
| 12/06/24 | 24.44 | -3.51% |
| 11/06/24 | 25.33 | -0.04% |
Real-time Boerse Frankfurt Warrants
Last update June 17, 2024 at 03:43 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UM1TF1 |
| ISIN | DE000UM1TF17 |
| Date issued | 19/02/2024 |
| Strike | 1,131 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 34.71 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.35 € |
|---|---|
| Lowest since issue | 22.4 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Certificates
- Certificat